MaxCyte Documents
Documents
100
Ticker
MXCT
ISIN
US57777K1060
MaxCyte SEC Filings
MaxCyte Documents 2026
This page contains all official documents and SEC filings for MaxCyte stock (MXCT, ISIN: US57777K1060). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of MaxCyte's regulatory filings.
MaxCyte Stock analysis
MaxCyte MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products.